Replimune Group (NASDAQ:REPL) Shares Down 6.4%

Replimune Group, Inc. (NASDAQ:REPL)’s share price was down 6.4% during mid-day trading on Monday . The stock traded as low as $10.42 and last traded at $10.42. Approximately 206,275 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 1,123,318 shares. The stock had previously closed at $11.13.

Analysts Set New Price Targets

A number of brokerages recently weighed in on REPL. Barclays raised their target price on shares of Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Monday. Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $16.00 target price on shares of Replimune Group in a research note on Thursday, June 6th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $16.20.

Replimune Group Price Performance

The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The company’s 50-day simple moving average is $10.19 and its 200-day simple moving average is $8.38. The stock has a market capitalization of $680.48 million, a P/E ratio of -3.51 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. As a group, sell-side analysts expect that Replimune Group, Inc. will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently bought and sold shares of the stock. Quest Partners LLC raised its stake in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares during the period. Algert Global LLC grew its holdings in shares of Replimune Group by 5.4% during the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after purchasing an additional 4,975 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Replimune Group by 8.1% during the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.